Status:
COMPLETED
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
Lead Sponsor:
Yueyue Li
Collaborating Sponsors:
Qilu Hospital of Shandong University
Zaozhuang Municipal Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-70 years
Brief Summary
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadrup...
Eligibility Criteria
Inclusion
- patients aged 18-70 years, regardless of gender;
- absent history of receiving H. pylori eradication therapy;
- diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.
Exclusion
- patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
- patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2025
Estimated Enrollment :
1730 Patients enrolled
Trial Details
Trial ID
NCT07167511
Start Date
January 1 2022
End Date
July 31 2025
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012